GlassScriptPhysician profile
Albert J Persia
NPI 1154310266
$9,659.82
in general payments reported to CMS, 2019-2025
47 companies · $2,189 in 2025
The $2,189 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $416 · 2021: $606 · 2022: $1,245 · 2023: $1,883 · 2024: $2,102 · 2025: $2,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,142.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,132.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $875.56 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $676.54 | 2019-2025 | |
| Abbvie INC. | $509.63 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $494.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $357.63 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $344.16 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $324.57 | 2019-2024 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $318.40 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $283.76 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.90 | 2019-2025 | Jardiance, Spiriva Respimat |
| Gilead Sciences, INC. | $200.76 | 2022-2024 | |
| Mylan Specialty L.P. | $191.97 | 2021-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $189.61 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $178.91 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $162.87 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $161.26 | 2024 | Symplicity G3 |
| Kvk-Tech, INC. | $160.66 | 2025 | |
| Merck Sharp & Dohme LLC | $154.71 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.67 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $118.37 | 2019-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $113.26 | 2022 | |
| Xeris Pharmaceuticals, INC. | $109.32 | 2024-2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $99.05 | 2024-2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $90.19 | 2023-2024 | Unithroid |
| Amarin Pharma, INC. | $89.29 | 2019-2022 | |
| Boston Scientific Corporation | $87.50 | 2025 | Watchman Flx |
| Baxter Healthcare | $87.36 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Lundbeck LLC | $76.92 | 2024-2025 | Rexulti |
| Viiv Healthcare Company | $66.95 | 2024-2025 | Apretude |
| Abbott Laboratories | $66.11 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $64.66 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $52.10 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $46.23 | 2019-2025 | Camzyos |
| Optinose US, INC. | $44.39 | 2022 | |
| Viatris Specialty LLC | $30.27 | 2025 | Yupelri |
| Insulet Corporation | $24.56 | 2024 | Omnipod |
| Hologic Sales and Service, LLC | $24.11 | 2024 | Aptima |
| Verona Pharma, INC. | $22.52 | 2025 | Ohtuvayre |
| Phadia US INC. | $21.23 | 2024 | Immunocap |
| Melinta Therapeutics, LLC | $20.46 | 2019 | |
| Corcept Therapeutics | $19.45 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.73 | 2023 | Xifaxan |
| Daiichi Sankyo INC. | $15.03 | 2021 | |
| Sanofi Pasteur INC. | $13.45 | 2019 | |
| Pacira Therapeutics, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Persia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.